UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB
(Mark One)
[X] Quarterly Report under Section 13 or 15(d) of the Securities Exchange
Act of 1934
For the quarterly period ended March 31, 2000.
[ ] Transition Report under Section 13 or 15(d) of the Securities Exchange
Act of 1934 (No Fee Required)
For the transition period from __________ to __________.
COMMISSION FILE NO. 333-68167
CARDIA, INC.
(Name of small business issuer in its charter)
MINNESOTA 41-1923885
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
13770 FRONTIER COURT, BURNSVILLE, MINNESOTA 55337-4720
(Address of principal executive offices including zip code)
(612) 997-2100
(Issuer's telephone number)
Indicate by check mark whether the registrant (1) filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the past 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]
Indicate the number of shares outstanding of each of the Issuer's
classes of common stock, as of the latest practical date: 1,200,053 shares of
Common Stock (par value $0.01 per share) outstanding on April 30, 2000.
<PAGE>
TABLE OF CONTENTS
Page
Number
------
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
Condensed Balance Sheets as of March 31, 2000 (Unaudited) and
December 31, 1999.................................................1
Condensed Statements of Operations (Unaudited) for the three
months ended March 31, 2000 and 1999.............................2
Condensed Statements of Cash Flows (Unaudited) for the three
months ended March 31, 2000 and 1999..............................3
Notes to Financial Statements (Unaudited)............................4
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operation...............................................5
Item 3. Quantitative and Qualitative Disclosures About Market Risk.............6
PART II - OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K.......................................7
Signatures ............................................................8
<PAGE>
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS.
CARDIA, INC.
CONDENSED BALANCE SHEETS
<TABLE>
<CAPTION>
MARCH 31, December 31,
2000 1999
------------ ------------
(Unaudited)
<S> <C> <C>
ASSETS
CURRENT ASSETS
Cash and equivalents $ 745,201 $ 753,768
Accounts receivable 153,468 157,466
Note receivable -- 156,602
Inventories 97,056 53,512
Prepaid expenses -- 7,430
------------ ------------
Total Current Assets 995,725 1,128,778
PROPERTY AND EQUIPMENT - NET 79,694 63,028
INTANGIBLE ASSETS - NET 62,499 66,666
------------ ------------
$ 1,137,918 $ 1,258,472
============ ============
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Trade accounts payable $ 37,735 $ 38,981
Accrued expenses 49,364 23,787
------------ ------------
Total Current Liabilities 87,099 62,768
SHAREHOLDERS' EQUITY
Preferred stock, $.01 par value; 1,000,000 shares
authorized; no shares issued or outstanding -- --
Common stock, $.01 par value;
10,000,000 shares authorized;
1,200,053 issued and outstanding 12,001 12,001
Additional paid in capital 2,882,626 2,882,626
Accumulated deficit (1,843,808) (1,698,923)
------------ ------------
1,050,819 1,195,704
------------ ------------
$ 1,137,918 $ 1,258,472
============ ============
</TABLE>
The accompanying notes are an integral part of these statements.
1
<PAGE>
CARDIA, INC.
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31,
-----------------------------
2000 1999
------------ ------------
<S> <C> <C>
Net Sales $ 381,628 $ 203,727
Cost of sales 79,786 106,113
------------ ------------
Gross profit 301,842 97,614
Operating Expenses
Selling, general and administrative 362,870 243,216
Research and development 91,049 18,062
------------ ------------
453,919 261,278
------------ ------------
Operating Loss (152,077) (163,664)
Interest income 7,192 --
------------ ------------
NET LOSS $ (144,885) $ (163,664)
============ ============
Net loss per common share - basic and diluted $ (0.12) $ (0.37)
============ ============
Weighted average common and common equivalent
shares outstanding - basic and diluted 1,200,053 441,666
============ ============
</TABLE>
The accompanying notes are an integral part of these statements.
2
<PAGE>
CARDIA, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31,
-----------------------------
2000 1999
------------ ------------
<S> <C> <C>
Cash flows from operating activities:
Net loss $ (144,885) $ (163,664)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization 10,216 4,167
Changes in Operating Accounts
Accounts receivable 3,998 (20,188)
Inventories (43,544) (1,112)
Prepaid expenses 7,430 8,664
Accounts payable (1,246) (11,703)
Accrued liabilities 25,577 18,560
------------ ------------
Net cash used in operating activities (142,454) (165,276)
Cash flows from investing activities
Purchase of property and equipment (22,715) (18,839)
------------ ------------
Net cash used in investing activities (22,715) (18,839)
Cash flows from financing activities
Proceeds from issuance of common stock -- 125,000
Advances made by Applied Biometrics, Inc. -- 222,771
Payments received on note receivable 156,602 --
------------ ------------
Net cash provided by financing activities 156,602 347,771
------------ ------------
NET INCREASE (DECREASE) IN CASH
AND EQUIVALENTS (8,567) 163,656
Cash and equivalents at beginning of period 753,768 500
------------ ------------
Cash and equivalents at end of period $ 745,201 $ 164,156
============ ============
</TABLE>
The accompanying notes are an integral part of these statements.
3
<PAGE>
CARDIA, INC.
NOTES TO FINANCIAL STATEMENTS
(Unaudited)
1. Organization
Cardia, Inc. is a Minnesota corporation that develops, manufactures and markets
transcatheter closure device products for the repair of certain cardiac defects.
Cardia also conducts research and development as well as clinical trials for its
closure devices. Future research and development activities are expected to
include further improvements and continued testing of Cardia's existing
technology, and investigation of modified devices for new applications. Cardia
anticipates performing animal pilot trials on those devices which appear to be
the most promising.
2. Basis of Presentation
The accompanying unaudited financial statements have been prepared pursuant to
the rules and regulations of the Securities and Exchange Commission. Certain
information and footnote disclosures normally included in annual financial
statements prepared in accordance with generally accepted accounting principles
have been condensed or omitted as permitted by such rules and regulations. These
financial statements and related notes should be read in conjunction with the
financial statements and notes thereto included in the Company's audited
financial statements for the year ended December 31, 1999 contained in the
Company's Annual Report on Form 10-KSB for 1999 previously filed with the
Commission.
In the opinion of management, the interim financial statements reflect
adjustments, consisting of normal recurring accruals, which are necessary to
present fairly the Company's financial position, results of operations and cash
flow for the periods indicated. The results of operations for the three months
ended March 31, 2000 are not necessarily indicative of the results to be
expected for the full year.
3. Net Loss Per Common Share
Basic net loss per common share is computed by dividing net loss by the
weighted-average number of outstanding common shares. Diluted net loss per
common share is computed by dividing net loss by the weighted average number of
outstanding common shares and common share equivalents, when dilutive. Common
stock equivalents, consisting of shares that might be issued upon exercise of
stock options are not included in weighted-average common shares for purposes of
determining diluted earnings per share in periods where losses are reported
since their inclusion would be antidilutive.
4
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
REVENUES. Revenues for the three months ended March 31, 2000 were
$381,628 as compared to revenues of $203,727 for the comparable period in 1999.
This increase is a result of additional sales and marketing efforts during the
quarter. In October 1999, Cardia received the CE mark for its products, which
allows the company to market its products throughout Europe. Currently, Cardia's
revenue is derived entirely from product sales in Europe.
GROSS PROFIT. Gross profit for the three months ended March 31, 2000
was $301,842, up from $97,614 in the same period of 1999. The gross profit
percent for the three months ended March 31, 2000 was 79%, up from 48% in the
same period of 1999. The increase in gross profit and gross profit percentage in
2000 can be attributed to increased revenues associated with Cardia's sales of
transcatheter closure devices as well as a decrease in the cost of sales due
largely to efficient manufacturing methods being implemented.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES. Cardia's selling, general
and administrative expenses for the first three months of 2000 were $362,870,
compared to $243,216 for the comparable period in 1999. The majority of these
expenses are attributable to Cardia's expansion of its sales and marketing
activities in 2000. These expenditures are variable and the amount spent during
the remainder of 2000 will depend largely on the performance and growth of
Cardia's business. Cardia does not expect to make material capital investments
in plant or equipment during the remainder of 2000. However, Cardia does expect
to add between two and five full-time employees during the remainder of 2000.
Those additional personnel will not be added, however, unless business growth
justifies additional employees.
RESEARCH AND DEVELOPMENT. Cardia's research and development expenses
for the first three months of 2000 were $91,049, compared to expenses of $18,062
during the same period of 1999. Research and development costs have increased as
continued improvements and further testing of the acquired technology have taken
place. In addition, Cardia has been investigating modified devices for new
applications.
NET LOSS. Cardia's net loss for the three months ended March 31, 2000
was $144,885, compared to a net loss of $163,664 for the same period of 1999.
The decrease in net loss was due largely to significantly increased revenues
coupled with significantly increased gross profits. These gains, however, were
mostly offset by increased operating expenses as discussed above.
LIQUIDITY AND CAPITAL RESOURCES. Cardia's liquidity as of March 31,
2000 consisted of approximately $745,201 in cash and $153,468 in accounts
receivable. Cardia's inventories were $97,056 as of March 31, 2000, compared to
$53,512 as of December 31, 1999. The increase is attributable to management's
estimate of required inventory to meet increased sales and marketing activities.
Cardia believes that its current liquidity will be sufficient to fund operations
for an estimated 12 months. Cardia intends to raise additional capital in the
next 12 to 18 months through the issuance of equity or debt securities or
through bank debt, or a combination of these means; however, no assurance can be
given that Cardia will be able to obtain additional financing from any source at
all or on terms favorable or acceptable to Cardia.
5
<PAGE>
FORWARD-LOOKING STATEMENTS
This form 10-QSB contains forward-looking statements that involve risks
and uncertainties. When used in this 10-QSB, the words or phrases "believes,"
"anticipates," "expects," "intends," "estimates" or similar expressions are
intended to identify forward-looking statements, but are not the exclusive means
of identifying such statements. These forward looking statements involve risks
and uncertainties that may cause our actual results to differ materially from
those expressed or implied by the forward-looking statements. It is not possible
to foresee or identify all factors affecting Cardia's forward-looking statements
and investors therefore should not consider any list of factors to be an
exhaustive statement of all risks, uncertainties or potentially inaccurate
assumptions. Factors that could cause actual results to differ from the results
discussed in the forward-looking statements include, but are not limited to, the
following factors: (i) the difficulties and obstacles inherent in obtaining
market acceptance for Cardia's cardiac closure devices which are completely new
products for treating cardiac defects and designed to serve as an alternative to
open heart surgery, the traditional treatment for such defects; (ii) the
potential liability risks inherent in the use of implantable medical devices and
Cardia's inability to be assured that the products liability insurance coverage
it maintains will provide adequate coverage against such potential liabilities;
(iii) the challenges and uncertainties associated with the lengthy and costly
regulatory clearance processes and ongoing compliance with the extensive
requirements of the United States Food and Drug Administration and foreign
governments with respect to implantable medical devices; (iv) the risks and
difficulties associated with developing international markets for Cardia's
products; (v) the fact that Cardia is an early stage company with limited
financial resources and an accumulated deficit of $1,843,808, and there can be
no assurance that required additional capital will be available to Cardia on
acceptable terms, if at all; and (vi) the lack of a current public market for
Cardia's common stock and an inability of the company to provide any assurance
that an active trading market will ever develop or, if developed, will be
sustained.
Readers are urged to carefully review and consider the various
disclosures made by Cardia in this report and in Cardia's other reports filed
with the Securities and Exchange Commission from time to time that attempt to
advise interested parties of the risks and factors that may affect Cardia's
business and results of operations. Cardia undertakes no obligation to revise
any forward-looking statements in order to reflect events or circumstances that
may arise after the date of this report.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Cardia's management believes that the market risk association with its
market risk sensitive instruments as of March 31, 2000 is not material, and
therefore, disclosure is not required.
6
<PAGE>
PART II - OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) EXHIBITS
The following exhibit is included with this Quarterly Report on Form
10-QSB as required by item 601 of Regulation S-B:
Exhibit 27. Financial Data Schedule
(b) REPORTS ON FORM 8-K
None.
7
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized, on March 12, 2000.
CARDIA, INC.
By /s/ Joseph A. Marino
--------------------------------
Joseph A. Marino
Chief Executive Officer,
President, and Treasurer
8
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
CARDIA, INC.
FINANCIAL DATA SCHEDULE
JANUARY 1, 2000 TO MARCH 31, 2000
</LEGEND>
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> MAR-31-2000
<CASH> 745,201
<SECURITIES> 0
<RECEIVABLES> 153,468
<ALLOWANCES> 0
<INVENTORY> 97,056
<CURRENT-ASSETS> 995,725
<PP&E> 96,654
<DEPRECIATION> (16,960)
<TOTAL-ASSETS> 1,137,918
<CURRENT-LIABILITIES> 87,099
<BONDS> 0
0
0
<COMMON> 12,001
<OTHER-SE> 1,038,818
<TOTAL-LIABILITY-AND-EQUITY> 1,137,918
<SALES> 381,628
<TOTAL-REVENUES> 381,628
<CGS> (79,786)
<TOTAL-COSTS> (533,705)
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 7,192
<INCOME-PRETAX> (144,845)
<INCOME-TAX> 0
<INCOME-CONTINUING> (144,845)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (144,845)
<EPS-BASIC> (0.12)
<EPS-DILUTED> (0.12)
</TABLE>
